Research programme: smoking withdrawal therapies - NovavaxAlternative Names: NX-301
Latest Information Update: 28 Jun 2005
At a glance
- Originator Novavax
- Class Alkaloids; Analgesics; Drug withdrawal therapies; Nicotine replacement therapy; Pyridines; Small molecules
- Mechanism of Action Nicotinic receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Smoking withdrawal
Most Recent Events
- 01 Jul 2005 Preclinical trials in Smoking withdrawal in USA (Transdermal)